Eyepoint Pharmaceuticals (NASDAQ:EYPT) Issues Quarterly Earnings Results

Key Points

• Imminent clinical catalysts: Phase III wet-AMD readouts (LUGANO mid-year, LUCIA shortly after) are expected soon and management says two positive IDMC safety reviews support DURAVYU; Phase III DME trials (COMO and CAPRI) are enrolling rapidly with full enrollment targeted in Q3 2026 and top-line data in H2 2027.
• Weak quarter but cash runway: Eyepoint reported an EPS miss of ($0.99) vs. ($0.79) expected while revenue of $0.7M beat estimates but fell sharply year-over-year; operating expenses were $88M and net loss $85M, with cash of $223M that management says funds the company into Q4 2027.
• Commercial and market positioning: Northbridge cGMP facility is online and pre-approval inspection preparations are underway as the company builds launch capabilities (new CCO added), while the stock trades around $13.35 with analysts holding an overall "Buy" consensus and a $32.20 average price target.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20), FiscalAI reports. The firm had revenue of $0.70 million for the quarter, compared to analysts' expectations of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%.

Here are the key takeaways from Eyepoint Pharmaceuticals' conference call:

• Phase III wet AMD readouts (LUGANO mid-year, LUCIA shortly after) are expected soon and management says two consecutive positive IDMC reviews support DURAVYU’s safety profile, which could be a near-term catalyst if top-line results are favorable.
• Phase III DME programs (COMO and CAPRI) are enrolling rapidly, with management targeting full enrollment in both pivotal trials in Q3 2026 and top-line data in H2 2027, driven by strong investigator and patient interest.
• Commercial and CMC readiness progressed—Northbridge cGMP facility is online, pre-approval inspection preparations underway, and the company added a Chief Commercial Officer as it builds launch capabilities for DURAVYU.
• Financials show pressure—Q1 revenue fell to $0.7M (from $24.5M a year earlier) due to prior deferred revenue recognition, operating expenses rose to $88M, and net loss was $85M; cash is $223M (down from $306M) though management expects runway into Q4 2027.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT traded down $0.40 during trading hours on Wednesday, reaching $13.35. The company had a trading volume of 1,214,757 shares, compared to its average volume of 856,506. Eyepoint Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $19.11. The firm has a market cap of $1.12 billion, a PE ratio of -4.22 and a beta of 1.76. The business's 50 day moving average price is $14.40 and its 200-day moving average price is $14.60.

Insider Transactions at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business's stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.46% of the company's stock.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. purchased a new position in Eyepoint Pharmaceuticals during the third quarter worth approximately $76,000. Tower Research Capital LLC TRC boosted its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after purchasing an additional 5,967 shares in the last quarter. California State Teachers Retirement System boosted its position in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock worth $85,000 after purchasing an additional 794 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in Eyepoint Pharmaceuticals during the fourth quarter worth approximately $98,000. Finally, Raymond James Financial Inc. boosted its position in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock worth $112,000 after purchasing an additional 1,177 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.

Wall Street Analyst Weigh In

EYPT has been the topic of several research analyst reports. HC Wainwright boosted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Citigroup boosted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, March 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Chardan Capital boosted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $32.20.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.